CRISPR Therapeutics AG (CRSP)
NASDAQ: CRSP · IEX Real-Time Price · USD
57.90
+1.09 (1.92%)
At close: Jul 12, 2024, 4:00 PM
58.73
+0.83 (1.43%)
Pre-market: Jul 15, 2024, 8:13 AM EDT

CRISPR Therapeutics AG Income Statement

Millions USD. Fiscal year is Jan - Dec.
Year Ending
TTM Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019 2018 - 2014
Revenue
271.71371.211.2914.960.72289.59
Upgrade
Revenue Growth (YoY)
171.01%30885.48%-99.87%127154.94%-99.75%9169.85%
Upgrade
Gross Profit
271.71371.211.2914.960.72289.59
Upgrade
Selling, General & Admin
71.7676.16102.4699.6985.7563.49
Upgrade
Research & Development
498.59517.58571.9441.75269.41179.36
Upgrade
Operating Expenses
570.35593.74674.36541.44355.15242.85
Upgrade
Operating Income
-298.64-222.54-673.16373.53-354.4446.74
Upgrade
Other Expense / Income
-83.79-71.82-22.66-6-6.38-20.57
Upgrade
Pretax Income
-214.84-150.72-650.5379.53-348.0667.31
Upgrade
Income Tax
2.292.89-0.331.870.810.45
Upgrade
Net Income
-217.14-153.61-650.18377.66-348.8766.86
Upgrade
Shares Outstanding (Basic)
827978766654
Upgrade
Shares Outstanding (Diluted)
827978806657
Upgrade
Shares Change
3.96%1.90%-3.29%21.90%15.84%18.70%
Upgrade
EPS (Basic)
-2.69-1.94-8.364.97-5.291.23
Upgrade
EPS (Diluted)
-2.69-1.94-8.364.70-5.291.17
Upgrade
Free Cash Flow
-166.55-269.85-532.93457.27-256.7249.99
Upgrade
Free Cash Flow Per Share
-2.04-3.41-6.866.02-3.890.92
Upgrade
Gross Margin
100.00%100.00%100.00%100.00%100.00%100.00%
Upgrade
Operating Margin
-109.91%-59.95%-56190.40%40.82%-49295.55%16.14%
Upgrade
Profit Margin
-79.91%-41.38%-54271.70%41.28%-48520.86%23.09%
Upgrade
Free Cash Flow Margin
-61.30%-72.69%-44484.89%49.98%-35705.70%17.26%
Upgrade
Effective Tax Rate
---0.49%-0.67%
Upgrade
EBITDA
-195.23-130.89-626.33397.48-338.8772.03
Upgrade
EBITDA Margin
-71.85%-35.26%-52281.14%43.44%-47131.02%24.87%
Upgrade
Depreciation & Amortization
19.6219.8424.1717.959.184.73
Upgrade
EBIT
-214.84-150.72-650.5379.53-348.0667.31
Upgrade
EBIT Margin
-79.07%-40.60%-54298.83%41.48%-48408.34%23.24%
Upgrade
Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).